Additive effects of another kind of HMG-CoA reductase inhibitor with different pharmacokinetics in the treatment of heterozygous familial hypercholesterolemia

Atherosclerosis. 2000 Dec;153(2):525-6. doi: 10.1016/s0021-9150(00)00626-2.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Female
  • Heterozygote
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacokinetics
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hyperlipoproteinemia Type II / drug therapy*
  • Hyperlipoproteinemia Type II / genetics
  • Male
  • Middle Aged

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors